Table 1.
Details of studies included in this analysis
| Study and Year (Reference) | Type | Patient Population and/or Specific Organism | Comparator Antibiotic | Most Relevant Outcome to Kidney Injury | Relative Risk Ratio (95% CI) | Total No. of Patients |
|---|---|---|---|---|---|---|
| Wunderink et al. 2003 (55) | RCT, DB | Nosocomial pneumonia | Linezolid and aztreonam | Drug-related SAE: “kidney failure” | 2.13 (0.19 to 23.32) | 623 |
| Jaksic et al. 2006 (56) | RCT, DB | Febrile, neutropenic patients with cancer | Linezolid | “Renal failure”, all cause | 3.03 (1.12 to 8.23) | 603 |
| Kohno et al. 2007 (40) | RCT, OL | Nosocomial PNA, cSSSI, or sepsis with MRSA | Linezolid | Treatment-related AE: “renal function abnormal” | 9.80 (1.18 to 81.71) | 151 |
| Lin et al. 2008 (43) | RCT, OL | Hospitalized patients with PNA or cSSSI | Linezolid | “Acute kidney failure” | 0.33 (0.01 to 8.05) | 142 |
| Wilcox et al. 2009 (41) | RCT, OL | Catheter-related bacteremia | Linezolid | “Kidney failure, acute” | 3.00 (0.82 to 10.99) | 726 |
| Corrado et al. 2010 (44) | RCT, DB | cSSSI | Ceftaroline | Serum creatinine ≥1.5 mg/dl and ≥50% increase | 2.38 (0.92 to 6.14) | 1340 |
| Wunderink et al. 2012 (42) | RCT, DB | Nosocomial PNA with MRSA | Linezolid | 0.5-mg/dl Increase in serum creatinine level if normal at baseline or 50% increase if abnormal at baseline | 2.16 (1.29 to 3.60) | 448 |
| Lodise et al. 2008 (35) | Cohort | Hospitalized patients | Linezolid | Serum creatinine increase of 0.5 mg/dl or 50%, whichever was greater, on at least 2 consecutive d | 1.63 (0.51 to 5.20)a | 265 |
| Rodriguez Colomo et al. 2011 (34) | Cohort | ICU patients with renal failure and known or suspected MR-GPC | Linezolid | Requirement for RRT | 0.33 (0.11 to 0.96) | 147 |
| Chan et al. 2011 (38) | Cohort | VAP with MRSA | Linezolid | Serum creatinine increase of 0.5 mg/dl or 50%, whichever was greater, on at least 2 consecutive d | 1.26 (0.15 to 10.76) | 113 |
| Davies et al. 2013 (36) | Cohort | Surgical ICU patients | Linezolid | “Injury” or more severe level of RIFLE criteria | 1.43 (0.91 to 2.26) | 545 |
| Fujii et al. 2013 (37) | Cohort | Hospitalized patients | Linezolid | Renal dysfunction was defined on the basis of the progression of CKD after treatment | 1.78 (1.03 to 3.05) | 270 |
| Peyrani et al. 2014 (39) | Cohort | VAP with MRSA | Linezolid | Serum creatinine increase of 0.5 mg/dl or 50%, whichever was greater, on at least two consecutive measurements | 1.37 (0.65 to 2.90) | 188 |
RIFLE criteria from ref. 57. 95% CI, 95% confidence interval; RCT, randomized, controlled trial; DB, double blinded; SAE, serious adverse event; OL, open label; PNA, pneumonia; cSSSI, complicated skin and skin structure infection; MRSA, methicillin–resistant Staphylococcus aureus; AE, adverse event; ICU, intensive care unit; MR-GPC, methicillin–resistant gram–positive cocci; VAP, ventilator-associated pneumonia.
a
For vancomycin dose <4 g/d.